Creo Medical Group (LON:CREO) Reaches New 1-Year Low – Here’s What Happened

Creo Medical Group PLC (LON:CREOGet Free Report)’s share price reached a new 52-week low on Tuesday . The stock traded as low as GBX 15.50 ($0.20) and last traded at GBX 15.95 ($0.20), with a volume of 449749 shares changing hands. The stock had previously closed at GBX 16.13 ($0.20).

Creo Medical Group Price Performance

The stock has a market cap of £57.88 million, a PE ratio of -266.67 and a beta of 0.86. The business has a fifty day simple moving average of GBX 21.19 and a two-hundred day simple moving average of GBX 28.37. The company has a current ratio of 3.24, a quick ratio of 2.19 and a debt-to-equity ratio of 29.96.

Insider Buying and Selling

In related news, insider Richard John Rees purchased 98,000 shares of the company’s stock in a transaction dated Thursday, October 24th. The shares were purchased at an average cost of GBX 20 ($0.25) per share, with a total value of £19,600 ($24,847.87). Also, insider Kevin Crofton purchased 2,916,666 shares of the business’s stock in a transaction that occurred on Monday, October 21st. The stock was bought at an average price of GBX 24 ($0.30) per share, for a total transaction of £699,999.84 ($887,423.73). 22.43% of the stock is owned by insiders.

Creo Medical Group Company Profile

(Get Free Report)

Creo Medical Group PLC, through its subsidiaries, researches, develops, manufactures, and sells medical devices and instruments in the United Kingdom. It is developing CROMA, an energy platform that combines bipolar radiofrequency for precise localized cutting and microwave energy for controlled coagulation, to provide physicians with flexible, accurate, and highly controllable devices delivered through a flexible endoscope.

Featured Stories

Receive News & Ratings for Creo Medical Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Creo Medical Group and related companies with MarketBeat.com's FREE daily email newsletter.